WilmerHale Advises Thermo Fisher Scientific on $9 Billion Acquisition of Clario

WilmerHale Advises Thermo Fisher Scientific on $9 Billion Acquisition of Clario

Client News

WilmerHale is advising longtime client Thermo Fisher Scientific, a global leader in scientific solutions, on the $9 billion acquisition of Clario, a leading provider of endpoint data solutions for clinical trials.

The acquisition is for $8.875 billion in cash at close, plus additional earnout and other payments dependent on future performance.

Clario integrates clinical trial endpoint data from devices, sites and patients, enabling pharma and biotech customers to collect, manage and analyze clinical evidence digitally across every phase of drug development, supporting faster, more confident trial decisions. The company’s platform has supported approximately 70% of FDA drug approvals over the past decade.

The deal by WilmerHale comes on the heels of WilmerHale advising Thermo Fisher in connection with its $4 billion acquisition of Solventum’s purification and filtration business, which closed in September.

Led by Hal Leibowitz and Andrew Bonnes, WilmerHale put together an exceptional cross-disciplinary team of 40 lawyers for the deal, including M&A, Tax, Real Estate, Licensing and Intellectual Property, Employment and Benefits, Privacy, Environmental, Government Contracts/FCPA/Regulatory, FDA/Healthcare Regulatory, Litigation, and German/EU law and regulation.

The WilmerHale team was: M&A: Hal Leibowitz, Andrew Bonnes, William Myer, Virginia Pavlick, Kyle Kessler, Jane Cha, Justin Flaumenhaft, Rebecca Beames, Gwen Ljung, Madeline Simpson; Tax: Meghan Walsh, Benjamin Kelsey; Real Estate: Douglas BurtonBrett Jackson, Armen Grigorian; Licensing and Intellectual Property: Stephen Gillespie, Aron Nimani; Employment and Benefits: Amanda Albert, Ciara Baker, Caroline Estey; Privacy: Kirk Nahra, Ali Jessani, Sarah Litwin; Environmental: David Gold, Katie Raitz, Tiana Wilson-Blindman; Government Contracts/FCPA/Regulatory: Barry Hurewitz, Leslie Harrelson, Jarrod Carman, Sydney Warren; FDA/Healthcare Regulatory: Bruce S. Manheim, Jr., Stephanie Hartmann, Nora Xu; Litigation: Rachael Kent; Germany/EU: Tobias Henn, Golo Weidmann, Martin Braun, Cornelia Gersch, Peter Gey.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.